{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:37:10Z","timestamp":1778218630951,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Abstract:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Eyelid and periorbital dermatitis remains a distressing and recalcitrant disease. Contact dermatitis remains the most common cause of eyelid and periorbital dermatitis. Ophthalmic solutions used in the treatment of ophthalmic conditions can often be the cause. This article is an update of our previous study, summarizing the contact allergens involved and the new test concentrations reported to investigate through patch testing. New insights found during the review are also documented.\n                  <\/jats:p>","DOI":"10.1089\/derm.2023.0033","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T11:33:41Z","timestamp":1686915221000},"page":"480-483","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Contact Dermatitis to Ophthalmic Solutions: An Update"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8225-0833","authenticated-orcid":false,"given":"Sally J.","family":"Ashton","sequence":"first","affiliation":[{"name":"From the,  Singleton Hospital, Swansea, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avad A.","family":"Mughal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Neath and Port Talbot Hospital, Port Talbot, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.05.035"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2006.00927.x"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15239"},{"issue":"6","key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2230.2012.04398.x","article-title":"Contact dermatitis to ophthalmic solutions","volume":"37","author":"Mughal AA","year":"2012","unstructured":"Mughal AA, , Kalavala M. Contact dermatitis to ophthalmic solutions. Clin Exp Dermatol. 2012; 37(6):593\u2013598.","journal-title":"Clin Exp Dermatol"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000424"},{"issue":"6","key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.23822\/EurAnnACI.1764-1489.190","article-title":"Allergic contact dermatitis by ophthalmological medications in Brazil: experience of a dermatology","volume":"53","author":"Chan YK","year":"2021","unstructured":"Chan YK, , Goto EN, , Criado RF, et al. Allergic contact dermatitis by ophthalmological medications in Brazil: experience of a dermatology. Eur Ann Allergy Clin Immunol. 2021; 53(6):280\u2013283.","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12448"},{"issue":"3","key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/cod.12808","article-title":"Allergic contact dermatitis caused by \u03f5-aminocaproic acid in a purified sodium hyaluronate ophthalmic solution","volume":"77","author":"Mitsuyama S","year":"2017","unstructured":"Mitsuyama S, , Abe F, , Kimura M, et al. Allergic contact dermatitis caused by \u03f5-aminocaproic acid in a purified sodium hyaluronate ophthalmic solution. Contact Dermatitis. 2017; 77(3):191\u2013192.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1346-8138.2010.00934.x","article-title":"Allergic contact dermatitis due to diclofenac sodium in eye drops","volume":"38","author":"Miyazato H","year":"2011","unstructured":"Miyazato H, , Yamaguchi S, , Taira K, et al. Allergic contact dermatitis due to diclofenac sodium in eye drops. J Dermatol. 2011; 38(3):276\u2013279.","journal-title":"J Dermatol"},{"issue":"2","key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2340\/00015555-2832","article-title":"Allergic contact dermatitis due to ripasudil hydrochloride hydrate in eye-drops: a case report","volume":"98","author":"Kusakabe M","year":"2018","unstructured":"Kusakabe M, , Imai Y, , Natsuaki M, et al. Allergic contact dermatitis due to ripasudil hydrochloride hydrate in eye-drops: a case report. Acta Dermato Venereol. 2018; 98(2):278\u2013279.","journal-title":"Acta Dermato Venereol"},{"issue":"1","key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/cod.13497","article-title":"Allergic contact dermatitis in response to ketotifen fumarate contained in eye drops","volume":"83","author":"Romita P","year":"2020","unstructured":"Romita P, , Stingeni L, , Barlusconi C, et al. Allergic contact dermatitis in response to ketotifen fumarate contained in eye drops. Contact Dermatitis. 2020; 83(1):35\u201337.","journal-title":"Contact Dermatitis"},{"issue":"1","key":"e_1_3_1_13_2","first-page":"1","article-title":"Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report","volume":"19","author":"Kim JH","year":"2019","unstructured":"Kim JH, , Kim HJ, , Kim SW. Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report. BMC Ophthalmol. 2019; 19(1):1\u20134.","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/cod.12716","article-title":"Contact allergy to thioctic acid present in Hypromellose\u00ae eye drops","volume":"76","author":"Craig S","year":"2017","unstructured":"Craig S, , Urwin R, , Wilkinson M. Contact allergy to thioctic acid present in Hypromellose\u00ae eye drops. Contact Dermatitis. 2017; 76(6):361\u2013362.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12478"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000626"},{"issue":"4","key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/cod.13730","article-title":"Periocular allergic contact dermatitis caused by brinzolamide","volume":"84","author":"Navarro-Trivi\u00f1o FJ","year":"2021","unstructured":"Navarro-Trivi\u00f1o FJ, , Ruiz-Villaverde R. Periocular allergic contact dermatitis caused by brinzolamide. Contact Dermatitis. 2021; 84(4):274\u2013276.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3109\/15569527.2011.552898","article-title":"Periocular allergic contact dermatitis following topical Mitomycin C eye drop application","volume":"30","author":"Cumurcu T","year":"2011","unstructured":"Cumurcu T, , Sener S, , Cavdar M. Periocular allergic contact dermatitis following topical Mitomycin C eye drop application. Cutan Ocul Toxicol. 2011; 30(3):239\u2013240.","journal-title":"Cutan Ocul Toxicol"},{"key":"e_1_3_1_19_2","first-page":"bcr","article-title":"Periocular contact dermatitis with use of topical voriconazole 1% in mycotic keratitis","volume":"2018","author":"Sahay P","year":"2018","unstructured":"Sahay P, , Asif MI, , Maharana PK, et al. Periocular contact dermatitis with use of topical voriconazole 1% in mycotic keratitis. Case Rep. 2018; 2018:bcr-2018.","journal-title":"Case Rep"},{"issue":"1","key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/ajd.12426","article-title":"Periorbital allergic contact dermatitis caused by lanolin in a lubricating eye ointment","volume":"57","author":"Higgins CL","year":"2016","unstructured":"Higgins CL, , Nixon RL. Periorbital allergic contact dermatitis caused by lanolin in a lubricating eye ointment. Austral J Dermatol. 2016; 57(1):68\u201369.","journal-title":"Austral J Dermatol"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000264"},{"issue":"4","key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11636020-000000000-00000","article-title":"Post-marketing surveillance of levofloxacin 0.5% ophthalmic solution for external ocular infections","volume":"12","author":"Kanda Y","year":"2012","unstructured":"Kanda Y, , Kayama T, , Okamoto S, et al. Post-marketing surveillance of levofloxacin 0.5% ophthalmic solution for external ocular infections. Drugs R&D. 2012; 12(4):177\u2013185.","journal-title":"Drugs R&D"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12695"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304197"},{"issue":"4","key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/cod.14245","article-title":"Topical eye medications causing allergic contact dermatitis","volume":"88","author":"Ahlstr\u00f6m MG","year":"2023","unstructured":"Ahlstr\u00f6m MG, , Skov L, , Heegaard S, et al. Topical eye medications causing allergic contact dermatitis. Contact Dermatitis. 2023; 88(4):294\u2013299.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/cod.13865","article-title":"Allergic contact dermatitis due to ripasudil in eye drops","volume":"85","author":"Sotozono A","year":"2021","unstructured":"Sotozono A, , Arakawa Y, , Tamagawa-Mineoka R, et al. Allergic contact dermatitis due to ripasudil in eye drops. Contact Dermatitis. 2021; 85(3):379\u2013380.","journal-title":"Contact Dermatitis"},{"issue":"1","key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/cod.13671","article-title":"Allergic contact dermatitis due to dorzolamide eyedrops","volume":"84","author":"Mitsuyama S","year":"2021","unstructured":"Mitsuyama S, , Abe F, , Higuchi T. Allergic contact dermatitis due to dorzolamide eyedrops. Contact Dermatitis. 2021; 84(1):58\u201359.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/cod.14174"},{"issue":"2","key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/cod.13826","article-title":"Contact allergy and allergic contact dermatitis from benzalkonium chloride in a tertiary dermatology center in Melbourne, Australia","volume":"85","author":"Dear K","year":"2021","unstructured":"Dear K, , Palmer A, , Nixon R. Contact allergy and allergic contact dermatitis from benzalkonium chloride in a tertiary dermatology center in Melbourne, Australia. Contact Dermatitis. 2021; 85(2):146\u2013153.","journal-title":"Contact Dermatitis"},{"issue":"4","key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/cod.12157","article-title":"Periorbital dermatitis in 4779 patients\u2013patch test results during a 10-year period","volume":"70","author":"Landeck L","year":"2014","unstructured":"Landeck L, , John SM, , Geier J. Periorbital dermatitis in 4779 patients\u2013patch test results during a 10-year period. Contact Dermatitis. 2014; 70(4):205\u2013212.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/cod.14168"},{"issue":"5","key":"e_1_3_1_32_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/cod.13209","article-title":"Allergic contact dermatitis caused by topical ophthalmic medications: keep an eye on it!","volume":"80","author":"Gilissen L","year":"2019","unstructured":"Gilissen L, , De Decker L, , Hulshagen T, et al. Allergic contact dermatitis caused by topical ophthalmic medications: keep an eye on it!. Contact Dermatitis. 2019; 80(5):291\u2013297.","journal-title":"Contact Dermatitis"},{"issue":"5","key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.anai.2017.03.004","article-title":"Severe delayed-type hypersensitivity to chloramphenicol with systemic reactivation during intradermal testing","volume":"118","author":"Watts TJ","year":"2017","unstructured":"Watts TJ. Severe delayed-type hypersensitivity to chloramphenicol with systemic reactivation during intradermal testing. Ann Allergy Asthma Immunol. 2017; 118(5):644\u2013645.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2020.11.006"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/OPTH.S29062","article-title":"Ocular hypotensive effect and safety of travoprost 0.004%\/timolol maleate 0.5% fixed combination after change of treatment regimen from \u03b2-blockers and prostaglandin analogs","volume":"6","author":"Inoue K","year":"2012","unstructured":"Inoue K, , Setogawa A, , Higa R, et al. Ocular hypotensive effect and safety of travoprost 0.004%\/timolol maleate 0.5% fixed combination after change of treatment regimen from \u03b2-blockers and prostaglandin analogs. Clin Ophthalmol. 2012; 6:231.","journal-title":"Clin Ophthalmol"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsi.2015.02.005"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000640"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000586"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/derm.2023.0033","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2023.0033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2023.0033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:07:05Z","timestamp":1777399625000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/derm.2023.0033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12,1]]}},"alternative-id":["10.1089\/derm.2023.0033"],"URL":"https:\/\/doi.org\/10.1089\/derm.2023.0033","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}